Stock TVGN TEVOGEN BIO HOLDINGS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Tevogen Bio Holdings Inc.

Equities

TVGN

US88165K1016

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/06/2024 am IST 		5-day change 1st Jan Change
0.75 USD +7.45% Intraday chart for Tevogen Bio Holdings Inc. -5.98% -93.26%
25/06 Tevogen Bio Holdings Inc. Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances CI
24/06 Tevogen Bio Holdings Inc.(NasdaqGM:TVGN) added to S&P TMI Index CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
GL
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
GL
Tevogen Bio Holdings Inc. Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
CI
Tevogen Bio Holdings Inc.(NasdaqGM:TVGN) added to S&P TMI Index
CI
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
GL
Tevogen Bio Set to Join Russell 3000® Index
GL
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
GL
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
GL
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
GL
Tevogen Bio Confirms Ongoing Efficacy of Tvgn 489, Its Investigational Allogeneic Off-The-Shelf Immunotherapy, Against Dominant Flirt Strains of Sars-Cov-2
CI
Tevogen Bio Reports First Quarter 2024 Financial Results
GL
Tevogen Bio Reports First Quarter 2024 Financial Results
AQ
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
GL
Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday
MT
Top Premarket Gainers
MT
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
GL
Tevogen Bio Holdings Inc. announced that it expects to receive $50 million in funding
CI
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
GL
Sector Update: Health Care Stocks Higher in Afternoon Trading
MT
Tevogen Bio Shares Jump Following Report on $94.9 Million Liability Elimination
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TVGN Stock
  4. News Tevogen Bio Holdings Inc.